Cello Group plc (CLL) Rating Reiterated by FinnCap

Cello Group plc (LON:CLL)‘s stock had its “buy” rating reiterated by FinnCap in a note issued to investors on Tuesday, StockTargetPrices.com reports. They presently have a GBX 132 ($1.72) price target on the stock. FinnCap’s price objective suggests a potential upside of 23.94% from the stock’s previous close.

Several other research analysts also recently weighed in on the stock. N+1 Singer reissued a “buy” rating and issued a GBX 128 ($1.67) target price (up from GBX 127 ($1.66)) on shares of Cello Group plc in a research report on Tuesday, September 20th. Cenkos Securities Ltd reissued a “buy” rating on shares of Cello Group plc in a research report on Wednesday, September 14th. Finally, Peel Hunt reissued a “buy” rating and issued a GBX 130 ($1.70) target price on shares of Cello Group plc in a research report on Tuesday, July 26th. Five investment analysts have rated the stock with a buy rating, The company presently has an average rating of “Buy” and a consensus price target of GBX 123.75 ($1.62).

Analyst Recommendations for Cello Group plc (LON:CLL)

Shares of Cello Group plc (LON:CLL) opened at 106.50 on Tuesday. The firm’s market cap is GBX 92.45 million. Cello Group plc has a 52-week low of GBX 77.10 and a 52-week high of GBX 115.00. The stock has a 50 day moving average of GBX 105.65 and a 200 day moving average of GBX 98.83.

The business also recently declared a dividend, which will be paid on Friday, November 4th. Investors of record on Thursday, October 6th will be issued a dividend of GBX 1 ($0.01) per share. This represents a dividend yield of 0.94%. The ex-dividend date of this dividend is Thursday, October 6th.

Cello Group plc Company Profile

Cello Group plc is a United Kingdom-based healthcare and consumer strategic marketing company. The Company is engaged in providing market research, consulting and direct marketing services. The Company operates through two segments: Cello Health and Cello Signal. The Cello Health Division provides market research, consulting and communications services principally to the Company’s pharmaceutical and healthcare clients.

Stock Target Prices

Receive News & Ratings for Cello Group plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cello Group plc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

© 2006-2016 Mideast Time.